

CONTENTS

<i>Chapter</i>	<i>Page</i>
1. Summary and Policy Options	1
Introduction	1
Summary	2
Clinical Significance of Recombinant Erythropoietin	2
Structure of the Recombinant Erythropoietin Marketplace	3
Medicare's Current Payment Policies	4
Dimensions for Evaluating Payment Options	6
Quality of Care	7
Access to Care	7
Cost and Efficiency	8
Equity	9
Technological Change	9
Administrative Feasibility	10
Options For Medicare Payment	11
General Options	14
Payment to Providers	20
Payment for the Product	31
Conclusion	40
2. Clinical Significance of Recombinant Erythropoietin	43
Introduction	43
Treatment of Anemia Associated with Chronic Renal Failure	43
Evaluation of the Efficacy of Recombinant Erythropoietin	47
Physiologic Effects of Recombinant Erythropoietin in Chronic Renal Failure Patients	47
Effects of Recombinant Erythropoietin on the Quality of Life in Chronic Renal Failure Patients	53
Other Potential Uses of Recombinant Erythropoietin	56
Evaluation of the Safety of Recombinant Erythropoietin	58
Adverse Effects of Recombinant Erythropoietin	58
Recombinant Erythropoietin and Blood Transfusions	61
Summary of Safety and Efficacy of Recombinant Erythropoietin	61
3. The Structure of the Marketplace *	63
Introduction	63
History of Discovery and Production	63
FDA Approval of Recombinant Erythropoietin	66
Recombinant Erythropoietin and Patent Disputes	67
Recombinant Erythropoietin and the Orphan Drug Act	68
The Supply Side of the Market for Recombinant Erythropoietin	70
Distribution of Recombinant Erythropoietin	71
The Demand Side of the Market for Recombinant Erythropoietin	72

CONTENTS--Continued

4. Recombinant erythropoietin: Medicare's Current Payment Policies	75
Introduction.....	75
Medicare's Payment Policies for ESRD Services.....	75
Medicare's Payment Policies for Pharmaceuticals.....	77
General Payment Policies.....	77
Prescription Drug Coverage Under the ESRD Program	78
Hepatitis B Vaccine.....	78
Immunosuppressive Drugs	79
Medicare's Current Coverage and Payment Policies for Recombinant erythropoietin	79
Dialysis Facilities	79
Physicians' Offices	80
Medicaid Coverage of Recombinant erythropoietin.....	82

Appendix

A. Method of the Study	83
B. Workshop Participant	84
C. Acknowledgements	85
D. Glossary of Terms and Acronyms.....	87
E. Method Used by the Office of the Inspector General to Estimate the Manufacturer's Costs of Recombinant erythropoietin	91
References	93

Boxes

Box	Page
2-A. Dialysis Treatment Methods	44

Tables

Table	Page
1-1. Options for Congress to Address Medicare Payment Related to Recombinant erythropoietin	11
1-2. Summary of Analysis of Congressional Options for Medicare Payment for Recombinant erythropoietin.....	12
2-1. Dialysis Treatment Methods Used in the United States by Medicare and Non-Medicare Patients, December 31, 1988	44
2-2. Home Dialysis Treatment Methods Used in the United States by Medicare and Non-Medicare Patients, December 31, 1988	45
2-3. Distribution of Hematocrit Levels of Dialysis Patients, by Age, January 1988	46
2-4. Efficacy and Safety Studies in Chronic Renal Failure Patients	48
2-5. Reduction in Blood Transfusions with Recombinant erythropoietin Therapy	50
2-6. Dose Response to Intravenous Recombinant erythropoietin	51
2-7. Studies of Subcutaneous Administration of Recombinant erythropoietin	52

CONTENTS--Continued

2-8.	Quality-of-Life Studies	55
2-9.	Adverse Reactions to Recombinant erythropoietin	58
2-10.	Percent of Patients Reporting Adverse Reactions from Recombinant erythropoietin	59
2-11.	Adverse Reactions to Recombinant erythropoietin Per Patient Year	59
3-1.	Milestones in the Development of Recombinant erythropoietin	64
3-2.	Recombinant erythropoietin Marketing Rights	65
3-3.	Recombinant erythropoietin Products with Orphan Drug Designations, March 1990	69
3-4.	Estimates of Individuals With Selected Conditions Who Are Anemic.....	73
3-5.	Projections of Medicare-Eligible Dialysis Patients Who Are Candidates for Treatment With Recombinant erythropoietin by Age Group, 1990-1995	73
4-1.	Coverage for Dialysis-Related Medical Services in the United States, December 31,1988.....	75
4-2.	Dialysis and Kidney Transplant Service Providers in the United States, November 1989.....	75
4-3.	Prices of a 4,000 Unit Vial to Providers of Recombinant erythropoietin, by Country, December 1989	81